www.xortx.com Open in urlscan Pro
35.157.97.117  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content Skip to footer
 * Home
 * About
   * Overview
   * Management Team
   * Board of Directors
   * Advisory Board
 * Pipeline
   * Overview
   * XRx-008 for Autosomal Dominant Polycystic Kidney Disease
   * XRx-101 for Coronavirus/COVID-19
   * XRX-225 for Type 2 Diabetic Nephropathy
   * Publications
 * Technology
 * News
   * Press Releases
   * Events
 * Investors
   * Overview
   * News & Events
   * Presentations
   * Company Info
   * Financial Info
   * Stock Data
   * SEC Filings
   * SEDAR
   * Governance
 * Contact


PIONEERING NEW THERAPIES FOR PROGRESSIVE KIDNEY DISEASE

We are XORTX Therapeutics, a biotechnology company dedicated to developing
innovative therapies to improve the quality of life of patients with progressive
kidney disease. Our programs are designed to manage aberrant purine metabolism
and reduce high uric acid and slow progression of kidney disease.

About our company



DEVELOPING FIRST-IN-CLASS URIC ACID LOWERING AGENTS

We have three programs, two of these programs are in clinical development and
one is at an early stage of development, each is intended to treat rare and
progressive kidney disease modulated by aberrant purine and uric acid
metabolism.

XRX-008 FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

We are currently developing XRx-008 for the treatment for progressive autosomal
dominant polycystic kidney disease (ADPKD), a genetic disorder that’s known to
cause declining kidney function leading to end stage kidney disease and
cardiovascular disease.

Learn More

XRX-101 FOR DISEASES CAUSED BY CORONAVIRUS INFECTIONS

XRx-101 is a novel proprietary formulation that focuses on decreasing uric acid.
The company believes that this approach has the potential to treat acute kidney
and other health consequences associated with serious viral infections such as
have been described for Coronavirus/COVID-19.

Learn More

XRX-225 FOR TYPE 2 DIABETIC NEPHROPATHY

We are co-developing XRx-225 for the treatment of Type 2 Diabetic Nephropathy
(T2DN), one of the most common causes of chronic kidney failure and end-stage
kidney disease in the U.S. and worldwide.

Learn More


REDEFINING KIDNEY DISEASE THROUGH STRATEGIC COLLABORATIONS

We believe there is a substantial benefit to collaborating with partners, that
is why we are always on the lookout for opportunities that will enable us to
develop and commercialize products that not only meet the needs of both patients
and physicians but will also help redefine the future of treatment options for
patients with progressive kidney disease.

About our partnerships


LATEST NEWS

View All News
May 5, 2022


XORTX OPENS AN IND FOR XRX-008 PROGRAM FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY
DISEASE

View Press Release
May 3, 2022


XORTX INITIATES DOSING OF HUMAN SUBJECTS IN THE XRX-OXY-101 CLINICAL TRIAL

Apr 20, 2022


XORTX RECEIVES SMALL AND MEDIUM ENTERPRISE STATUS FOR THE EUROPEAN UNION


EMAIL ALERTS

Receive updates straight into your inbox

Sign up today


STOCK SNAPSHOT

XORTX THERAPEUTICS INC.

View Detailed Stock Information
   
 * Nasdaq
   
   
 * TSX Venture Exchange
   

Market/Symbol

NASDAQ: XRTX

Last

$1.74

Change

0.14 (8.75%)

Volume

297.55k

Day Range

1.6101 - 1.90

Year Range

0.9615 - 8.1851

Market/Symbol

TSX-V: XRTX

Last

$2.20

Change

0.24 (12.24%)

Volume

19.33k

Day Range

2.15 - 2.47

Year Range

1.44 - 9.979
©2022 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless
otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End
of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.